DARA BioSciences, Inc. Launches Soltamox®, First and Only Liquid Version of Tamoxifen Citrate

Published: Oct 22, 2012

RALEIGH, N.C.--(BUSINESS WIRE)--Breast Cancer Awareness Month raises visibility and research dollars to address a disease that in the United States claims nearly 40,000 lives annually and affects approximately 240,000 people who each year are newly diagnosed. While the month’s activities are important in the fight against breast cancer, they are not designed to directly improve the day-to-day management of the disease. But today, a liquid version of one of the most common drugs prescribed to fight breast cancer, tamoxifen, has for the first time become available in the United States under the brand name Soltamox® (tamoxifen citrate). Soltamox may offer patients who need tamoxifen therapy an important treatment option. Introduced by DARA BioSciences, Inc. (NASDAQ: DARA), a specialty pharmaceutical company focused on oncology and oncology supportive care products, Soltamox, a prescription medication, is expected to be available in pharmacies nationwide starting October 22.

Back to news